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Abstract 
For two decades, leukemia stem cells (LSCs) in chronic myeloid leukemia 
(CML) and acute myeloid leukemia (AML) have been advanced paradigms for the 
cancer stem cell field. In CML, the acquisition of the fusion tyrosine kinase BCR-
ABL1 in a hematopoietic stem cell (HSC) drives its transformation to become a LSC. 
In AML, LSCs can arise from multiple cell types through the activity of a number of 
oncogenic drivers and pre-leukemic events - adding further layers of context and 
genetic and cellular heterogeneity to AML LSCs that is not observed in most cases 
of CML. Furthermore, LSCs from both AML and CML can be refractory to standard-
of-care therapies and persist in patients, diversify clonally, and serve as reservoirs to 
drive relapse, recurrence or progression to more aggressive forms. Despite these 
complexities, LSCs in both diseases share biological features, making them distinct 
from other CML or AML progenitor cells and from normal HSCs. These features may 
represent Achilles’ heels against which novel therapies can be developed. Here, we 
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review many of the similarities and differences that exist between LSCs in CML and 
AML and examine therapeutic strategies that could be used to eradicate them. 
 
The authors dedicate this review to our absent colleague Tessa Laurie Holyoake, 
whose untimely passing in 2017 cut short the life of a brilliant clinician and scientist. 
Her discovery of the quiescent CML LSC in 1999, her dedication to the pre-clinical 
study of LSCs in the years that followed and her commitment to cure CML, paved 
the way for many of the scientific discoveries discussed here. 
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[H1] Introduction 
CML and AML account for approximately half of new cases of leukemia 
worldwide (Surveillance, Epidemiology, and End Results Program: 
https://seer.cancer.gov/ and Cancer Research UK: 
https://www.cancerresearchuk.org/). CML, the rarer of the two by incidence, is a 
clonal myeloproliferative disease characterised by leukocytosis and an accumulation 
of granulocytes and their precursors. The Philadelphia chromosome [G] (Ph+)1-3 and 
the constitutive expression of the fusion protein BCR-ABL1 are the unique hallmarks 
of CML cells. Most CML patients present in relatively benign chronic phase (CP), but 
if left untreated, the disease will progress to myeloid or lymphoid blast phase (BP) 
where it mirrors an acute leukemia4. Development of tyrosine kinase inhibitors (TKIs) 
targeting BCR-ABL1 (hereafter referred to simply as TKIs) two decades ago has 
revolutionised the management of CML (Figure 1). Approximately 80% of CP 
patients achieve excellent disease control at five years5, 6 on TKI therapy, and this 
figure rises to ~90% at 10 years7. Of these patients, ~10% remain in therapy-free 
remission (TFR) upon TKI discontinuation8, 9. However, TKI therapy is less 
successful in approximately 25% of CP patients due to resistance or intolerance, and 
this is more common in patients with BP-CML and in those CP patients who 
progress to BP whilst on a TKI (close to 100%)4. Overall, the five-year relative 
survival rate [G] now exceeds 90% and, for this reason, CML is predicted to become 
the most prevalent form of leukemia within 30 years10. 
At the other extreme of the clinical and molecular spectrums is AML – one of 
the commonest acute leukemias. It shares similarities with BP-CML including an 
increased frequency of blast cells, aggressiveness and poor prognosis. However, the 
molecular defects underlying AML are considerably more heterogeneous than in 
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CML, with at least 24 different genetically-defined sub-types11, 12. The standard 
treatment for AML is cytotoxic chemotherapy that impairs DNA and RNA synthesis, 
and consists of a backbone of 7 days of cytarabine followed by 3 days of 
anthracycline. This therapy dates back to the 1970s, and novel targeted therapies for 
AML are limited and most have only been approved very recently13-15  (Figure 1). For 
those AML patients who achieve remission, the relapse rate is ~50% and the five-
year overall survival rate is a dismal ~ 30%16. 
Despite these differences, both CML and AML arise from, and are maintained 
by, LSCs. The earliest observational evidence of LSCs in myeloid leukemia dates 
back to the 1960-1980s17-20, and seminal discoveries in the 1990s provided the first 
empirical evidence of LSCs in patients21, 22 (Figure 1). Subsequent work supported 
the long-held view that LSCs in both CML and AML are refractory to standard-of-
care therapies23-27 – a view that has been challenged more recently28, 29. 
Disappointingly, novel therapies that eradicate AML or CML LSCs have still not 
reached clinical practice. This begs the question – what must we still learn in order to 
eradicate LSCs? In this Review we examine the experimental and clinical evidence 
for CML and AML LSCs and highlight many of the features they share. However, 
there are clear differences between LSCs in both diseases, some of which challenge 
consensus views in the field and raise new questions. 
[H1] Defining therapy-naïve LSCs 
[H2] Cell surface marker definitions. The expression of CD34 and lack of CD38 
(CD34+CD38-) on the cell surface is a pattern commonly associated with 
hematopoietic stem cells (HSCs) residing at the apex of the hematopoietic hierarchy, 
and was the first immunophenotype [G] associated with LSCs in both diseases21, 22, 
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30. Apart from one report to the contrary31, CD34+CD38- cells are generally accepted 
as the principal immunophenotype in which CP-CML LSCs reside. However, LSCs in 
BP-CML reside in multiple immunophenotypes normally associated with less 
primitive hematopoietic cells32, 33, as well as within the CD34- sub-fraction34. In this 
respect, BP-CML mirrors AML, in which LSCs are also found in a variety of CD34+ 
and CD34- immunophenotypes23, 35-37. Analysis of transcriptional profiles and multi-
lineage differentiation capacity of AML LSCs bearing immunophenotypes other than 
CD34+CD38-, have demonstrated that these LSCs arise from more mature cells that 
have acquired self-renewal capacity and are not derived from more primitive “HSC-
like” cells that have gained expression of markers of more mature myeloid cells36, 38-
40. However, it is dangerous to infer that LSC cell surface marker expression 
accurately reflects the expression patterns found in normal hematopoietic cells and 
the identification of a growing list of LSC-selective cell surface markers (Box 1) 
further blurs such comparisons. 
[H2] Functional definitions. LSCs are defined functionally as leukemic cells that 
are capable of self-renewal and are thus able to exhibit sustained survival in 
optimised ex vivo co-culture systems41, 42, and engraftment into 
immunocompromised mice21, 30, 35. Engraftment is considered the gold-standard 
assay defining the leukemia initiating cell (LIC) – a term used interchangeably with 
LSC in the AML literature43. Across several studies, ~50-90% of AML patient 
samples have been shown to engraft in various immunocompromised mice35, 36, 44 
and engraftment levels directly correlate with LSC frequency in samples and in ex 
vivo co-cultures45, and with poor clinical outlook46, 47. Patient samples are also 
capable of serial engraftment21, 30, 48 thus demonstrating that AML LSCs are highly 
competent at self-renewal and this may exceed the competency exhibited by 
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HSCs48. Engraftment in limiting dilution experiments has also provided quantitative 
estimates of the frequencies of AML LSCs in samples at ~0.2 to several thousand 
per million mononuclear cells21, 30, 35, 49. The caveat here is that improvements over 
the last decade to immunocompromised strains that express human cytokines50 or 
remove the requirement for irradiation of mice51-53  have meant that increases in the 
proportion of AML samples that engraft54 and the level to which they engraft50, 54-56 
have been observed in the newer strains. Thus, how we functionally define LSCs in 
AML and estimate the number of LSCs found in patient samples may be subject to 
change as new strains continue to be developed.  
Whilst we know that all CML patients have LSCs at diagnosis22, the rigorous 
functional definitions used in AML have not been possible, for the most part, in CML. 
This is because the vast majority of CML patient samples do not engraft well in 
immunocompromised mice. The exception to this is in BP-CML, where the proportion 
of patient samples that engraft is higher than in CP-CML and often at moderate to 
high levels of chimerism [G] (although cohort sizes in these studies were small)33, 34, 
57. For these reasons, it remains challenging to establish correlations between 
engraftment potential and prognosis in CP-CML or BP-CML. Interestingly, of those 
CP-CML samples that do engraft, chimerism rarely exceeds a few percent57 and the 
mice don’t develop leukemia, confirming earlier work that CP-CML LSCs have 
compromised self-renewal potential42. This challenges the view that LSCs and LICs 
are functional equivalents in CML and is further supported by elegant experiments 
using a BCR-ABL1 transgenic mouse model58 which revealed that some LSCs are 
capable of engraftment only, whilst others are capable of both engraftment and 
leukemogenesis59.  
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[H2] Cycling versus quiescence. Slow cycling or quiescence, along with self-
renewal, have long been considered requirements of both CML and AML LSCs22, 60, 
61 to prevent their exhaustion and counter the effects of leukemic proliferation. There 
is ample evidence which demonstrates how LSC quiescence is controlled at the 
molecular level, for example, by growth factors60, miRNAs62, or pathways involving 
the regulators CBP/p300-interacting transactivator 2 (CITED2) and peroxisome 
proliferator-activated receptor γ (PPARγ)63. Again there are exceptions to the 
assumed requirement for quiescence, as some LSCs have characteristics of actively 
cycling cells35, 40, 64. To try and reconcile these differences, studies in both diseases 
have shown that LSCs can be reversibly quiescent22, 48, 59, 60 and this feature can be 
exploited experimentally to drive quiescent LSCs into cycle 63, 65, 66. However, based 
on the limited engraftment and leukemogenic capacities of CP-CML LSCs, these 
may have somewhat reduced cycling potential or some may even be irreversibly 
quiescent. 
[H2] Biochemical definitions. High reactive oxygen species (ROS) levels in bulk 
CML and AML cells, compared to normal haematopoietic cells, are often explained 
through the actions of oncogenic kinases like BCR-ABL1, FLT3 or KRAS, which 
increase the activities of RAC GTPases,67, 68 or the actions of of membrane-bound 
NADPH oxidases,69, 70 which correlate with increased dependence of leukemic cells 
on mitochondrial respiration71, 72. However, extremes in ROS levels (too high or too 
low) present problems to LSCs, as these extremes can promote differentiation and 
impair stem cell function69, 73. Indeed, LSCs in CML and AML appear to be very 
different in how they deal with ROS to enable their survival. CP-CML LSCs, including 
quiescent sub-populations, have high ROS relative to either HSC or bulk CML 
cells67, 74, demonstrating they can tolerate high levels of ROS and may lack efficient 
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strategies to reduce them. Inhibition of BCR-ABL1 with TKIs does not significantly 
reduce ROS74 – suggesting that BCR-ABL1 kinase activity alone does not determine 
steady-state ROS levels. Furthermore, high ROS might explain why CP-CML LSCs 
have impaired self-renewal potential42. Quiescent AML LSCs, however, generally 
have low ROS levels compared to cycling LSCs and bulk AML cells75, 76 and unlike 
CP-CML LSCs, they appear highly proficient at reducing ROS. In some situations, 
they may achieve this by either reverting to glycolysis77, thus reducing dependence 
on mitochondrial respiration which generates ROS, or by using mitophagy to recycle 
damaged mitochondria76 that are prone to premature electron leakage to oxygen, 
generating ROS. Neither of these features has been explored in CML, and although 
CML LSCs have high levels of autophagy in murine models66, this is clearly not 
sufficient to maintain a low ROS environment.  
Regardless of how CML and AML LSCs regulate ROS levels, both invariably 
fail to effectively repair the consequences of ROS – oxidative DNA damage. Such 
damage drives genetic evolution of LSCs, typified by the high mutation burden and 
genomic instability observed in BP-CML and AML78, 79. Even in CP-CML, evidence 
points to LSCs having increased error prone repair80 that suppresses apoptosis81, or 
utilization of alternative homologous recombination repair pathways82 (all reviewed 
further elsewhere83, 84). Importantly, impaired DNA repair also provides a mechanism 
to explain how quiescent AML LSCs75 acquire mutations (albeit at lower levels) even 
in the absence of high ROS levels. Alternatively, the high mutation burden in AML 
may be driven by cycling LSCs 35, 40, 64, 85 which have higher ROS as noted above 
and whose clonal expansion is likely to give them competitive advantages. It’s also 
worth noting that mutations can accrue in LSCs even in the presence of TKIs74 since 
neither high ROS or aberrant DNA damage repair in CP-CML are driven by BCR-
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ABL1 kinase activity67, 74, 82. This is at odds with one study that suggested TKI-
resistant LSCs have a low mutator phenotype86, and whether LSCs in CP-CML 
patients on TKIs are prone to acquiring new mutations is still an unresolved issue. 
[H2] Molecular definitions. Arguably the most unequivocal definitions of LSCs lie 
within their global molecular profiles. Studies in AML have led the way in 
demonstrating that, irrespective of the oncogenic driver, or the immunophenotype, 
LSCs display mRNA or epigenetic signatures based on small subsets of genes that 
are similar to, but distinguishable from, signatures found in HSCs and normal 
multipotent hematopoietic progenitors35, 87-89. The exception to this appears to be 
MLL (also known as KMT2A)-rearranged AML, where LSCs possess similarities to 
an mRNA signature from embryonic stem cells40. Such signatures have excellent 
prognostic value35, 87-89 and have been used as drug discovery tools to identify 
compounds, such as antihistamines, that target AML LSCs in vitro90. These seminal 
studies35, 87-89 suggest that simple ‘stemness’ metrics can unify diverse AML LSC 
sub-classes provided they are studied in combination with engraftment readouts and 
undertaken in reasonably large sample cohorts. Global mRNA and epigenetic 
profiling has also been performed on LSCs from CP-CML and BP-CML patients, but 
only in small sample cohorts (n=3-6)82, 91-93. The limited scope of these studies, plus 
the issues associated with engrafting CML samples in mice, has precluded using the 
same approaches pioneered in AML to identify predictors of clinical outcome in CML.  
[H1] Origins and evolution of LSCs 
[H2] Pre-leukemia. Strong evidence in AML points to the origins of LSCs in 
pre-leukemic cells that arise through the sequential accumulation of somatic DNA 
mutations in HSCs. The consequences of these ‘early’ mutations are enhancement 
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or acquisition of self-renewal potential and often impairment of differentiation94, 95, 
both of which can lead to variably expanded clonal populations of pre-leukemic 
HSCs in patients96, 97. ‘Late’ mutations in molecules within signalling pathways, for 
example FLT3, promote proliferation, impose a full differentiation block and drive the 
development of AML98, 99. Mutations in genes encoding epigenetic regulators (eg., 
DNA methyltransferase 3A (DNMT3A), the methylcytosine dioxygenases TET1, and 
TET2, isocitrate dehydrogenase 1 (IDH1), IDH2, the Polycomb group protein ASXL1, 
and cohesin complex components)96, 97 and TP53 (which encodes p53)100 are some 
of the commonest ‘early’ mutational events in AML and one or several pre-leukemic 
mutations are found in a majority of AML patients101. These mutations can, in part, 
be attributed to the effects of compromised DNA repair leading to clonal 
hematopoeisis of indeterminant potential [G] (CHIP). CHIP is a known risk factor for 
hematological malignancy and has a peak incidence in the general healthy 
population of ~15-20% after age 70102, 103.  
A minority (~15-20%) of CP-CML patients carry putative pre-leukemic 
mutations104, 105, a frequency one could attribute to CHIP and not causal or pre-
disposing to CML. Two studies have shown that approximately a third of these 
mutations (in ~5-7% of CP-CML cases) are antecedent to the acquisition of BCR-
ABL1 in the same clone104, 105 and these patients may have a worse clinical 
outcome105. In a separate study, the incidence of mutations often seen as pre-
leukemic events in AML was shown to increase to ~50-60% in the small proportion of 
CP-CML patients who progressed to BP106. Thus, while pre-leukemic mutations may 
only play a relatively minor causal or predisposing role in developing CP-CML, they 
are likely to be a significant risk factor in developing aggressive BP disease and 
AML. This is consistent with the hypothesis that CP-CML primarily arises from a 
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single mutation “hit” (i.e, BCR-ABL1), while BP-CML and AML require two or more 
“hits” – one of which may be highly dependent on mutations arising from CHIP. 
[H2] Emergence of LSCs and hierarchies. The wealth of immunophenotypic, 
genetic and functional evidence indicates that LSCs in BP-CML and AML can 
originate from HSCs or from cells in later stages of the hematopoietic hierarchy48, 89, 
107, 108 (Figure 2). The situation in CP-CML, however, is very different. Since the 
acquisition of BCR-ABL1 may impair self-renewal, this necessitates that LSCs arise 
only in cells with high inherent self-renewal - such as CD34+CD38- HSCs107, or 
perhaps even more primitive hemangioblasts [G] 109. However, acquisition of BCR-
ABL1 alone, in one mouse model, was not sufficient to induce leukemia110, 
suggesting that additional genetic variants - possibly pre-leukemic ones - may also 
be required. Furthermore, the identification of multiple sub-types of HSCs111, LSCs 
that are non-leukemogenic59, and individuals who never develop CML but have Ph+ 
blood cells112, suggests that the formation of a CP-CML LSC from an HSC, and the 
ability of this LSC to drive leukemogenesis, is highly context-dependent. Overall, the 
evidence points to CP-CML LSCs emerging from one or more specific sub-types of 
HSC, whose unique features are not yet fully understood.  
The various routes by which LSCs can arise also raise the question whether 
there are functional hierarchies between the different LSC populations that reside in 
individual CML and AML patients. At one extreme are the flat LSC hierarchies; in 
CP-CML, these manifest as LSCs residing within the CD34+CD38- cell population22 
and these LSCs are most similar to HSCs immunophenotypically. However, flat 
hierarchies also exist in both BP-CML33 and CD34- AML37, but in these situations, 
there are multiple seemingly independent immunophenotypes of LSCs (and in this 
respect these LSCs are most divergent from HSCs) that show little or no semblance 
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of hierarchical organization. Between these two extremes lie the majority of AML 
cases, which display deeper, somewhat variable, hierarchies of LSCs. In support of 
this, AML LSCs originating from CD34+CD38- HSCs often show superior engraftment 
and self-renewal capacity compared to those found in other immunophenotypes30, 89, 
108. Furthermore, some AML LSC immunophenotypes within a sample can give rise 
to other engraftable immunophenotypes, but the converse is not always true36. The 
situations described here are undoubtedly over-simplified and do not take into 
account LSC-selective cell surface markers (Box 1) or the stochastic effects of 
epigenetic plasticity113, 114 on a continually evolving genetic background, both of 
which likely result in further intra- or inter- clonal hierarchies. With this in mind, it is 
unlikely that any AML or CML LSC hierarchy is ever truly flat.  
[H2] LSCs during therapy. Studies of the effects of standard-of-care therapies on 
LSCs have yielded further insights into their biology and evolution. Recent evidence 
from AML has shown that both quiescent and cycling AML LSCs are highly sensitive 
to chemotherapy, refuting that AML LSCs are refractory to treatment28, 29. By 
contrast, pre-leukemic AML cells can survive chemotherapy97, 115, 116. In CML, TKI 
treatment is ineffective at targeting LSCs in all phases of disease and a population of 
quiescent LSCs persists in the majority of CP patients - even in those patients in 
very deep remission24-26. A plausible explanation for this, supported by the anti-
proliferative effects of TKIs on LSCs in ex vivo studies117, 118, points to TKIs driving 
an adaptive ‘quiescence’ response in LSCs that alters their gene expression profile, 
enabling them to survive TKI therapy. In support of this, single cell analysis has 
clearly shown that CP-CML patients being treated with TKIs have persisting LSC 
populations enriched for quiescent transcriptional signatures119, 120 and the 
proportion of these cells increases in patients on more prolonged treatment120. Such 
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adaptive effects are also observed in AML - where transcriptional signatures and 
metabolic properties observed in chemotherapy-resistant cells 28, 29 are distinct from 
‘stemness’ signatures found in therapy-naïve LSCs35, 87. Another possibility is that 
CML LSCs are inherently TKI-resistant because they do not require BCR-ABL1 
expression for survival121, 122. This may also help explain why patients undergoing 
TKI therapy have persisting LSCs with low BCR-ABL1 expression86; in other words, 
TKIs may select for BCR-ABL1 independent LSCs.  
[H2] LSCs and disease relapse or recurrence. AML clonal representation at 
disease relapse reflects continued LSC evolution in many patients during remission. 
At relapse, minor clones present from diagnosis may emerge as dominant ones, or 
founder clones re-emerge with new sub-clonal structures123, 124. Even in the rare 
instances of very late relapse, residual LSCs from founder clones are the usual 
cause125. In many reported cases, new mutations, particularly transversions, are 
present in the relapse clones123, 124, suggesting chemotherapy itself induces DNA 
damage that accelerates LSC clonal diversification106, 107. Leukemic cells that persist 
after chemotherapy also have increased ROS levels28 (Figure 2), providing another 
mechanism to increase mutational burden and drive further clonal diversification. 
Although pre-leukemic HSCs have not been shown to give rise to leukemic clones 
driving relapse, AML patients with a high burden of pre-leukemic HSC clones show a 
poor clinical outcome95, 116. Overall, clonal evolution preceding the onset of AML and 
that occurring during chemotherapy are both important contributors to driving relapse 
and determining prognosis.  
  Unlike the situation in AML, a high overall burden of pre-leukemic HSCs in 
CML do not worsen response to TKIs or drive disease progression, but a pre-
leukemic lesion in a Ph+ clone can105. Moreover, whilst chemotherapy exacerbates 
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DNA damage that could drive further LSC clonal evolution, TKIs do not. Yet, 
although most CP-CML patients on TKI therapy remain in stable remission, some 
patients relapse or progress to BP-CML due to the emergence of Ph+ clones carrying 
BCR-ABL1 kinase domain mutations (such as T315I) or mutations in other genes 
linked to TKI resistance126, 105, 106. Emergence of new mutations during therapy most 
likely occur from TKI-induced selective pressure that enriches for TKI-resistant LSC 
clones harboring mutations that arose early in tumorigenesis (as pre-leukemic 
lesions, in some instances)104, 105, a view supported by clinical observations of the 
mutational burden present at diagnosis106, 127, 128. This would suggest that the clinical 
outlook of many CML patients may already be pre-determined even before frontline 
TKI therapy begins. 
One poorly understood phenomenon is why half of the CML patients who 
qualify for TKI discontinuation have molecular disease recurrence within 12 months, 
whilst the rest remain in deep remission8, 9. LSC clones that lack leukemia-initiating 
potential has been discussed as one possible explanation59 for those patients that 
remain in TFR. Alternatively, the immune system or the Ph- HSCs that reside 
alongside LSCs may play a role. Given the recent evidence that the presence of Ph- 
HSCs can discriminate TKI responders from non-responders120, it is plausible that 
these HSCs may have fitness advantages allowing them to out-compete residual 
LSC clones in those patients who remain in remission. Reports that TKIs may 
facilitate Ph- clonal hematopoiesis in some patients129, 130, adds further support for 
this view.  
[H1] LSC epigenetic and metabolic axes  
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[H2] Epigenetic re-patterning. Numerous studies point to LSCs having unique 
patterns of DNA methylation88, 131, histone modifications such as methylation of 
histone H3 lysine 4 (H3K4)132, H3K2793, and H3K79133, and chromatin accessibility95, 
108, when compared with HSCs or leukemic blasts. Importantly, there are quantifiable 
levels of intercellular heterogeneity associated with these changes95, 134. Pre-
leukemic mutations in epigenetic regulators (DNMT3A, TET1, TET2, IDH1 and 
IDH2)96, 97 provide the most obvious underlying basis for epigenetic re-patterning in 
AML and BP-CML. However, whilst DNA methylation patterns observed in patients 
can be specific to pre-leukemic lesions135, 136, variable patterns within similar genetic 
backgrounds can also occur137, whilst other patterns can be primarily independent of 
the genetic background88, 134. Given these different scenarios, the re-patterning that 
occurs in LSCs is likely to be complex. It can be driven by co-operativity or 
antagonism between two or more genetic mutations131, 136, or through changes to 
regulatory programmes as a result of dysregulated expression of transcription 
factors88, 138, 139 and epigenetic regulators such as lysine demethylase 1A 
(KDM1A)140, the histone-lysine N-methyltransferases EZH293, 141 and DOT1L133, the 
deacetylase sirtuin 1 (SIRT1)142, and the bromodomain and extra-terminal (BET) 
family protein BRD4143 amongst others. Indeed, there is ample evidence to support 
dysregulated expression of epigenetic regulators as a mechanism underlying 
epigenetic re-patterning in CP-CML (reviewed elsewhere144), given that most 
patients lack mutations other than BCR-ABL1. Predictably, there are functional 
consequences arising from these epigenetic changes: for example, up-regulation of 
self-renewal by the HOXA (AML)88, 145 or WNT–β-catenin (CP-CML)146, 147 pathways, 
blocking differentiation by GATA2-driven transcriptional programmes (AML)131, or up-
regulation of mitochondrial metabolism (CP-CML)148. However, epigenetic changes 
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also have other functional consequences in LSCs, including repression of 
apoptosis93, 144. 
Like clonal genetic evolution, epigenetic re-patterning has important 
implications in the clinic. DNA methylation signatures can predict survival in AML88, 
108 or are biomarkers of progression to BP-CML (reviewed elsewhere144). 
Furthermore, AML patients with high levels of intercellular heterogeneity in global 
DNA methylation have worse clinical outcome, and further increases of this 
heterogeneity are evident at relapse134. Strikingly, epigenetic signatures in AML are 
more predictive of outcome than genetic background134, suggesting that underlying 
epigenetic mechanisms may represent a unifying feature and a priority for drug 
discovery. However, this enthusiasm needs to be tempered with evidence that AML 
LSCs are hypo-methylated compared to AML blast cells88, suggesting that hypo-
methylating agents (eg., azacytidine) may be ineffective at eradicating them. 
Furthermore, whilst BET inhibitors (BETi) have shown pre-clinical evidence at 
targeting CML LSCs92, evidence from AML suggests that drug resistance to BETi is 
driven by LSC clones with altered epigenetic landscapes,149 which are likely to arise 
through selection from a background of high epigenetic intercellular heterogeneity.  
[H2] Metabolic alterations. The relationships between cellular metabolism and 
epigenetics in normal and cancer biology are now well recognized150. Therefore it 
should come as no surprise that mutations in metabolic enzymes such as IDH1 and 
IDH2 impact on both epigenetic re-patterning and metabolic states in LSCs. Indeed, 
many pathways involved in the catabolic processes regulating glucose, amino acid 
and free fatty acid levels are amongst those altered in LSCs71, 75, 151, 152. It is likely 
that the interplay between these metabolic processes and epigenetic readouts is 
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extensive in AML and CML LSCs (Figure 3), although their precise relationships and 
how they differ from other AML and CML cells have not yet been fully explored. 
Non-mutated IDH1 and IDH2 catalyse the conversion of isocitrate to the 
tricarboxylic acid (TCA) cycle intermediate alpha-ketoglutarate (α-KG) and generate 
NADPH. Mutant IDH catalyses NADPH-dependent reduction of α-KG to the 
oncometabolite 2-hydroxyglutarate (2-HG), which acts as a competitive inhibitor of 
α-KG-dependent dioxygenases153, 154. This gain-of-function activity dramatically 
increases 2-HG levels in leukemic patients, disrupts TET2 function and leads to DNA 
hyper-methylation135 and its associated down-stream effects on gene expression, 
cell proliferation and differentiation155, 156. Indeed, small molecule inhibitors targeting 
mutated IDH1 and IDH2 have been developed to reverse these effects (discussed in 
the next section).  
Whilst glycolysis in the presence of oxygen is a well-known feature of most 
cancer cells (the Warburg effect157), HSCs in the oxygen-poor bone marrow 
microenvironment also rely on glycolysis158, rather than oxidative phosphorylation 
[G] (OXPHOS) to fuel energy requirements. This suggests that inhibiting glycolysis 
will have detrimental effects on both normal hematopoiesis and leukemia cells. 
Indeed, depletion of lactate dehydrogenase A (LDHA), a glycolytic enzyme that 
catalyses the production of lactate, compromises both HSC function and 
leukemogenesis in mice159. However, recent studies have shown that primitive AML 
and CML cells including LSCs have higher mitochondrial mass and an increased 
oxygen consumption rate compared with normal cells71, 72, making them more reliant 
on mitochondrial function and OXPHOS (although exceptions to this exist in AML77). 
Indeed, inhibiting mitochondrial translation of proteins required for OXPHOS, using 
tigecycline, has anti-LSC effects in pre-clinical AML and CML models71, 72 More 
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recently, the novel electron transport chain complex I inhibitor, IACS-010759, 
inhibited OXPHOS and nucleotide biosynthesis by decreasing aspartate levels in 
AML cells160. Quiescent, low-ROS AML LSCs75, 76 also overexpress BCL-2 and are 
dependent on amino acid uptake and OXPHOS75, 161, 162. These features can be 
targeted using a combination of a BCL-2 inhibitor (BH3-mimetic [G]; venetoclax) and 
the DNA hypo-methylating agent azacitidine to synergistically inhibit the TCA cycle, 
suppress OXPHOS, and disrupt energy production163. Primitive AML cells have low 
spare mitochondrial respiration capacity that renders them sensitive to increased 
mitochondrial oxidative stress and cell death in situations when higher levels of 
OXPHOS are required164.  
Fatty acid metabolism is also emerging as a critical process in LSC survival. 
Expression of the lipoxygenases ALOX5 and ALOX15, enzymes involved in 
metabolism of polyunsaturated fatty acids, are upregulated in CML and loss of either 
of these causes a defect in LSC function165, 166. Whilst the mechanism(s) of how lipid 
metabolites, produced by ALOX5 and ALOX15, affects LSCs is largely unknown, it 
has been shown that fatty acid oxidation can be utilised by a sub-population of LSCs 
to enable drug-resistance in atypical niches rich in adipose tissue151. In these 
situations, fatty acid oxidation is most evident in LSCs expressing the fatty acid 
transporter CD36 – a feature preserved in a sub-set of LSCs in both BP-CML and 
AML151. Intracellular branched-chain amino acid (BCAA) metabolism has also been 
shown to be altered in CML, as elevated expression of the cytosolic form of BCAA 
aminotransferase 1 (BCAT1) is required for propagation of BP-CML152. BCAT1 
inhibition promotes differentiation, and impaired leukemogenesis and self-renewal of 
LSCs in CML mouse models, possibly through inhibition of BCAA-mediated mTOR 
complex 1 (mTORC1) activation152. BCAT1 inhibition also impairs AML cell survival 
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and increased mRNA levels of BCAT1 are also found in samples from AML patients 
with poor prognosis152 - suggesting that BCAT1 also plays a role in AML. 
[H1] The promise of novel therapies  
[H2] Novel CML therapies. Although LSCs persist in most patients on TKI 
therapy24-26 and a minority of these patients will achieve TFR167, it may be that we do 
not need to eliminate every LSC in patients who have minimal residual disease in 
order to achieve TFR - providing LSC levels can be maintained below a certain 
threshold in patients. This could be achieved through restoration of a healthy 
immune system, competition with normal HSCs, or because of functional limitations 
of persisting LSCs discussed above. In fact, recent evidence from a TKI 
discontinuation trial (DESTINY) would suggest that TKI dose de-escalation prior to 
discontinuing treatment may be a better option than sudden TKI discontinuation for 
maintaining TFR, likely via effects on residual LSCs or immunological control168.  
However, the significant clinical need to develop therapies for patients with 
resistance to TKIs in all phases of CML has focussed research on the development 
of novel kinase inhibitors that are effective in the presence of BCR-ABL1 kinase 
domain mutations. Ponatinib was the first TKI developed that demonstrated efficacy 
against the T315I mutant169, 170. Further novel kinase inhibitors, including PF-114171 
and the allosteric BCR-ABL1 inhibitor asciminib (ABL-001)172 have followed and are 
now in clinical trials (Table 1). Data is extremely limited regarding effects on LSCs for 
these novel agents and whether targeting BCR-ABL1 kinase activity alone will be 
sufficient to eliminate them is an open question.  
Numerous novel compounds that target survival factors or other molecular 
targets in LSCs have been identified in pre-clinical studies, a proportion of which 
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exhibit synthetic lethality in combination with a TKI (reviewed elsewhere83, 144). Some 
of these compounds have been, or are currently being, investigated in the clinic 
(Table 1) to either overcome therapy resistance or to obtain even deeper molecular 
responses in patients who have responded optimally to TKIs with a view to achieving 
TFR for more patients8, 167. However, not all of these compounds have been tested 
pre-clinically for activity against LSCs – but this warrants further investigation. Whilst 
pre-clinical evidence from AML suggests that a window of opportunity may exist 
during remission where LSCs may be vulnerable to novel agents such as dopamine 
receptor antagonists29, at this time, there is no evidence to suggest that CML 
patients in TFR would benefit from treatment with novel agents only. The alternative 
is safely combining these agents with TKIs used in the CML clinic, which is currently 
very challenging, given the high benchmark established with TKIs for patient care. 
There are numerous examples of CML trials investigating novel agents in 
combination with TKIs that closed early; reasons for this include lack of evidence for 
superior efficacy, increased or unacceptable toxicity or poor recruitment. For 
example, in preclinical studies, the Hedgehog pathway was a promising target in 
CML LSCs173, 174. However, when Smoothened (SMO) inhibitors that block the 
Hedgehog pathway were combined with TKIs (BMS-833923 with dasatinib, and 
LDE225 with nilotinib) in CML patients, no efficacy was seen and the toxicity profile 
was unacceptable in preliminary data from clinical trials175, 176. SMO antagonists, in 
particular glasdegib, have shown modest success for treatment of AML in the 
elderly, in combination with low-dose cytarabine177, 178. However, no clinical studies 
have specifically evaluated the effect of glasdegib against AML LSCs.  
Despite these caveats, some clinical agents have shown promise at reducing 
BCR-ABL1 mRNA levels when combined with TKIs in CML trials (Table 1). Imatinib, 
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the first TKI developed to target BCR-ABL1179, combined with pulsed granulocyte 
colony-stimulating factor (G-CSF) reduced the number of quiescent CML LSCs in 
pre-clinical studies180. The combination of intermittent imatinib (3 weeks out of 4), 
with G-CSF (3 times in the week off imatinib) or intermittent imatinib alone showed 
modest improvements in reducing BCR-ABL1 levels when compared to continuous 
imatinib therapy181. Interestingly, G-CSF has been combined with conventional 
chemotherapy in high-risk and relapsed/refractory AML cases, but results have been 
conflicting182, 183. Interferon-α was the mainstay of CML therapy prior to the 
introduction of TKIs (Figure 1) and it is thought to have effects on CML survival 
pathways, the immune system, and the bone marrow microenvironment184. Initial 
studies hinted that pre-treatment with interferon-α may result in improved TFR rates8; 
this may be by reducing LSCs levels, inhibiting their proliferation, or an effect on the 
immune system or bone marrow niche, and more recent clinical trials have safely 
combined TKI with interferon-α185 with further studies ongoing. In pre-clinical studies, 
the PPARγ agonist pioglitazone in combination with one of two different TKIs 
demonstrated synthetic lethality by decreasing the STAT5–HIF2α–CITED2 pathway, 
and reducing the quiescent LSC population63. In a cohort study, the combination of 
pioglitazone with imatinib resulted in substantially deeper remissions in patients 
compared to those on imatinib alone186 and this combination is now being assessed 
prospectively in several clinical trials (EudraCT2009-011675-79187, NCT02889003188, 
NCT02852486189, NCT02767063190, NCT02730195191). There has been limited 
exploration of PPARγ as a therapeutic target in AML192. 
[H2] Novel AML therapies. Arguably the greatest differences between CML and 
AML LSCs are evidenced by considering how treatment pathways have evolved for 
the two leukemias in recent years (Figure 1). Given the mutational heterogeneity in 
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AML, the cellular diversity within its LSC populations and their propensity to clonally 
evolve, identifying effective LSC therapies, particularly for relapsed/refractory AML, 
is hugely challenging. Thus, whilst TKIs have been standard-of-care in CML for two 
decades, it is only in the last two years, that we have seen successful clinical trials 
and regulatory approval of targeted therapies for AML13-15 – some of which are 
discussed below. However, these novel agents are unlikely to be the “magic bullet” 
that TKIs are for CML. 
[H2] Inhibitors of pre-leukemic lesions. Given the prevalence of pre-leukemic LSC 
clones bearing mutations in epigenetic regulators, developing approaches which 
target these mutant proteins is particularly attractive. Enasidenib, the clinically 
approved allosteric inhibitor of mutant IDH2 (present in 15-25% AML patients), or 
ivosidenib, an inhibitor of mutant IDH1 (present in 5-10% AML patients), reduce the 
levels of the onco-metabolite 2-HG, reduce the DNA hypermethylation caused by 2-
HG and promote differentiation of leukaemic blasts193-195. However, whether either 
drug affects the metabolic state or DNA methylation in LSCs is not clear. Treatment 
with enasidenib or ivosidenib led to remission in ~40%196, 197 or ~30%195, 
respectively, of patients with relapsed/refractory AML. However, in most enasidenib 
or ivosidenib responsive patients, the IDH1 and IDH2 mutant clones were not 
eliminated195-198, eventually resulting in relapse. A second IDH1 mutation in cis to the 
first one, or a second IDH2 lesion in trans to the first one, can result in patients 
relapsing due to acquired resistance to ivosidenib or enasidenib respectively199. 
Other mechanisms of resistance to enasidenib include mutations in IDH1, or clonal 
evolution of IDH2 mutant clones that have acquired other mechanisms of resistance 
despite continued inhibition of mutant IDH2 in patients at relapse198. Given the 
incidence of IDH1 and IDH2 mutations in BP-CML106, lessons learned from these 
Vetrie et al. (2019)      NRC-17-023   
23 
 
inhibitors in AML, may inform therapeutic options for a proportion of BP-CML 
patients with these mutations. 
[H2] FLT3 inhibitors. In FMS-like tyrosine kinase-3 (FLT3)-mutated AML the 
picture is a little different. FLT3 is a receptor tyrosine kinase expressed on primitive 
hematopoietic cells that activates the MAPK and PI3K–AKT pathways200. The FLT3-
internal tandem duplication (ITD) is present in ~30% of AML cases, leads to 
constitutive activation of STAT5, and correlates with poor prognosis. ATP-
competitive inhibitors of FLT3, e.g. midostaurin, sorafenib, quizartinib, and gilteritinib, 
have shown clinical efficacy in FLT3-ITD AML as single agents, but almost all 
patients relapse within months (reviewed elsewhere13, 15) – limiting their value in the 
clinic as monotherapies. This may be due to the fact that FLT3 mutations occur late 
during AML LSC evolution, and relapse could be driven by LSC clones with wild-type 
FLT3 antecedent to those with FLT3-ITD mutations as some researchers have 
suggested15. Combinatorial therapeutic approaches of FLT3 inhibitors with 
conventional chemotherapy or hypomethylating agents are also being extensively 
explored in AML clinical trials13, 15, 201, 202. As with BCR-ABL1 in CML, point mutations 
in the tyrosine kinase domain of FLT3 that drive resistance have been reported203, as 
well as FLT3-independent resistance mechanisms, including suppression of 
apoptosis204, activation of AXL, JAK and PIM kinases by cytokines produced within 
the bone marrow niche205, and autocrine production of  high levels of the FLT3 
ligand206. Whether such kinase-independent resistance mechanisms share 
similarities in AML and CML is not known, but studies examining such cross-over 
warrant consideration.  
[H2] Venetoclax. Although the anti-apoptotic BCL-2 family of proteins are not 
mutated in AML, inhibitors of these proteins, such as BCL-2 specific venetoclax, are 
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promising therapies161, 207, 208. High levels of BCL-2 are expressed in the therapy-
naïve LSC population in AML75, and there is increasing evidence that BCL-2 
inhibitors can also target LSCs in CML209-211 with clinical trials ongoing (Table 1). 
Furthermore, the incorporation of recently approved venetoclax14 into therapeutic 
strategies in AML is expected to improve therapeutic outcomes207, 208. Of particular 
note, venetoclax has shown synergism with hypomethylating agents and low-dose 
cytarabine in older patients where these combinations extend median patient 
survival to more than 16 months208. As discussed above, these combinations inhibit 
the metabolic dependency on OXPHOS in LSCs163 – thus providing a strategy to 
target this metabolic dependency in both AML and CML.  
[H1] Concluding remarks 
Here we have outlined the biological features of CML and AML LSCs and 
novel therapeutic approaches that have the potential to target these cells in the 
clinic. However, to fully unlock the potential of novel LSC-directed therapies, we 
need a greater understanding of the targetable features of individual LSC clones, 
their evolution and resistance mechanisms. Recent advances in single cell 
analysis120, 212, cellular bar-coding111, 213 and further application of computational 
models of LSC evolution214 will become increasingly instrumental to this end. Our 
knowledge of the leukemic bone marrow niche must greatly improve as many LSC 
vulnerabilities are, in part, niche-directed (reviewed elsewhere215, 216). Measuring 
metabolic alterations in the leukemic niche77, and using intravital microscopy217 to 
visualise its three-dimensional cellular and histological sub-structures will be critical. 
Immune checkpoint inhibitors218 and monoclonal antibodies against CD33219 or 
against LSC-selective cell surface markers (Box 1),  may hold the key to allow more 
patients to achieve TFR in both AML and CML. CAR-T cell-based therapies220, 221 
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may also prove critical for improving AML and BP-CML patient survival, although 
their efficacy at eradicating LSC is currently not known. Given all these exciting 
areas to explore, we look forward to a time when eradicating LSCs is no longer a 
current challenge, but a mere footnote in history. 
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Table of contents summary  
This Review discusses many of the similarities and differences between leukemia 
stem cells (LSCs) in chronic myeloid leukemia and acute myeloid leukemia and 
examines therapeutic strategies that could be used to eradicate these LSCs. 
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Table 1: Ongoing CML clinical trials evaluating novel agents.*  
DRUG‡ TARGET PATIENT POPULATION  TRIAL 
REFERENCE§ 
PRE-CLINICAL 
EVIDENCE†  
Asciminib 
(ABL001) 
BCR-ABL1 CML (all phases) 
Ph+ ALL (relapse/refractory) 
 
CP CML (TKI failure) 
NCT02081378 
 
 
NCT03106779 
222 
PF-114 BCR-ABL1  CML (all phases; TKI-resistant or 
T315I) 
NCT02885766 171 
Ruxolitinib JAK1 and JAK2 CP CML 
 
CML (all phases) 
 
CP CML 
 
CP CML 
 
CML 
NCT01702064 
 
NCT02253277 
 
NCT02973711 
 
NCT03654768 
 
NCT01751425 
223  
ETC-1907206 
 
MNK1 and MNK2 AP and BP CML 
Ph+ and Ph- ALL 
NCT03414450 224 
IFN- 
(AOP2014 or 
P1101)  
 
 
IFNα receptor 
(IFNAR) 
CML (in remission)  
 
CP CML (newly diagnosed) 
 
CP CML (newly diagnosed) 
 
NCT03117816 
 
NCT02201459 
 
NCT01657604 
 
225 
Vetrie et al. (2019)      NRC-17-023   
39 
 
 CP CML NCT01933906 
BP1001 
(antisense 
oligonucleotide) 
GRB2 mRNA CML NCT02923986 226 
Pioglitazone PPARγ  CML (relapsed) 
 
CP CML (in deep remission; TFR) 
 
CP CML 
 
CML (all phases) and Ph+ ALL 
NCT02889003 
 
NCT02852486 
 
NCT02767063 
 
NCT02730195 
63 
Axitinib BCR-ABL1  CML (all phases - resistance) NCT02782403 227 
Venetoclax  BCL-2 CP CML (newly diagnosed) NCT02689440 210 
Avelumab  PD-L1 CP CML  NCT02767063 228 
Nivolumab PD-1 CP and AP CML (TKI failure) NCT02011945 228 
Inecalcitol Vitamin D analogue CP CML (not in deep remission) NCT02949570 229 
*A detailed description of all current/potential AML therapies in clinical trials is 
beyond the scope of this review. 
‡All novel agents shown in the table, with the exception of PF-114, are being tested 
in combination with at least one or more standard-of-care TKIs that target BCR-ABL1 
(imatinib, dasatinib, nilotinib, bosutinib or ponatinib).  
† With the exception of Asciminib, PF-114 and Axitinib, pre-clinical evidence includes 
evidence of activity against LSCs. . 
§Trial reference refers to IDs found at https://clinicaltrials.gov/. 
 
 
CML milestones Type Date Reference 
busulfan clinical 1953 230 
Philadelphia chromosome identified scientific 1961 1, 2 
hydroxyurea clinical 1964 231 
allogeneic stem cell transplant clinical 1978 232 
evidence of LSC clonal origin scientific 1974 19 
interferon α clinical 1983 233 
BCR-ABL1 fusion identified scientific 1983 3 
evidence of LSCs in long-term co-culture scientific 1992 42 
quiescent Ph+ LSCs found in patients scientific 1999 22 
imatinib clinical 2002 179 
LSCs insensitive to TKIs in vitro scientific 2002 117 
LSCs detected in patients on TKIs scientific 2003 26 
dasatinib and nilotinib clinical 2006-2007 234, 235 
~10% CML patients safely discontinue TKI 
treatment 
clinical 2010 8, 9 
BCR-ABL1 kinase independent LSCs scientific 2011 121, 122 
bosutinib and ponatinib clinical 2012 169, 236 
altered epigenomes in LSCs scientific 2016 93 
LSCs dependent on OXPHOS scientific 2017 71 
single cell LSC transcriptomes scientific 2017 120 
CML patient 10-year survival > 90% clinical 2017 7 
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AML milestones Type Date Reference 
prednisone, 6-mercaptopurine, methotrexate, 
vincristine 
clinical 1965 237 
slow cycling cells in patients scientific 1963 17 
7 + 3 chemotherapy clinical 1973 238 
allogeneic stem cell transplants clinical 1977 239 
engraftment of human LSCs in mice scientific 1994 21 
evidence of LSCs in long-term co-culture scientific 1997 41 
LSC clones are hierarchical scientific 1997 30 
CD33 Ab-drug conjugate gemtuzumab ozogamicin clinical 2000 219 
LSC mRNA signatures predict survival scientific 2011 35 
altered epigenomes in LSCs scientific 2011 133 
pre-leukemic HSCs identified scientific 2012 96, 97 
LSCs dependent on OXPHOS scientific 2013 75 
LSC clonal evolution at relapse scientific 2017 123 
quiescent LSCs sensitive to therapy scientific 2017 28, 29 
midostaurin (FLT3), enasidenib (IDH2), ivosidenib 
(IDH1), venetoclax (BCL-2) 
clinical 2017 163, 195-197, 207, 208, 
240 
AML patient 5-year survival < 30% clinical 2019 16 
 
Figure 1. Scientific and clinical milestones relevant to CML and AML LSCs. The 
timelines highlight important milestones in CML and AML LSC research and track 
them chronologically alongside milestones linked to clinical care – some of which are 
referred to in the text. Relevant references linked to scientific and clinical milestones 
are noted on the figure. Clinical milestones for the various treatments shown on the 
timeline are dated from when they were first approved for, or became routinely used 
as, standard-of-care. 7 + 3 chemotherapy used in the treatment of AML refers to 7 
days of cytarabine followed by 3 days of anthracycline. Currently, imatinib is front-
line therapy for CML, whilst dasatinib, nilotinib, bosutinib and ponatinib are approved 
second-line therapies for patients with resistance or intolerance to imatinib. All five of 
these TKIs inhibit BCR-ABL1 kinase activity and have efficacy, to varying degrees, 
against BCR-ABL1 kinase domain mutations. Ponatinib is the only TKI with efficacy 
against the BCR-ABL1 T315I mutation.  
Figure 2. The evolving LSC. Models for how CML and AML LSCs arise, and evolve 
during disease progression and/or as a result of therapies (see further discussion 
and references in the main text). CP-CML LSCs arise when BCR-ABL1 is acquired 
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in normal hemangioblasts and HSCs, which decreases their self-renewal potential. In 
BP-CML or AML, LSCs can arise from either HSCs or more mature normal 
progenitor cells. When arising from progenitors, evidence suggests that LSCs would 
need to acquire self-renewal capacity first via pre-leukemic 1st hits (for example, 
mutations in DNMT3A or IDH1 amongst others), followed by acquisition of oncogenic 
2nd hits (for example, the BCR-ABL1 fusion protein or FLT3 mutations). Alternatively, 
BP-CML can arise via disease progression from a minor CP-CML clone that has 
acquired one or more 2nd hits (such as mutations in DNMT3A or IDH1). The 
possibility also exists that LSCs arising from HSCs can also acquire new mutations 
in their more mature progeny giving rise to additional LSC clones – but this is not 
depicted in this figure for simplicity. As a result of increased ROS and DNA damage, 
LSC clones diversify further by acquiring additional mutations – the exception being 
most cases of CP-CML, where mutation burden remains low. In the absence of 
additional mutations in CP-CML LSCs, robust responses to TKI treatment lead to 
residual disease being maintained by TKI-insensitive quiescent LSCs. Complete or 
partial resistance to TKIs can also arise from clonal selection of a minor clone 
carrying BCR-ABL1 kinase mutations such as T315I that expand during TKI therapy. 
In AML, disease relapse after 7 days of cytarabine followed by 3 days of 
anthracycline (7 + 3 chemotherapy) is driven by the major founder clone which has 
acquired additional mutations, or through expansion of a minor founder clone. In BP-
CML, response to a TKI is usually transient, and relapsed BP-CML is likely to follow 
similar clonal evolution as relapsed AML. 
Figure 3. The epigenetic and metabolic axis in LSCs. The schematic diagram 
depicts many of the known relationships between glycolysis, the TCA cycle, fatty 
acid and amino acid metabolism, and epigenetic processes150, 241, 242 in eukaryotic 
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cells. Exemplar proteins that have been shown to be survival factors or mutated in 
CML and/or AML (reviewed elsewhere83, 144, 243) and with known roles in metabolism 
or epigenetic processes are shown (purple ovals). In CML LSCs, free fatty acid 
(linoleic acid, stearic acid and oleic acid) levels are reduced, while carnitine and 
acetylcarnitine are increased – suggestive of increased lipolysis and fatty acid 
oxidation71. This process is believed to be linked to expression of the fatty acid 
transporter CD36 in atypical LSC niches151. Enzymes involved in fatty acid 
metabolism (ALOX5 and ALOX15) are known survival factors in CML165, 166 – 
although their roles in CML LSC metabolism is not known. Production of acetyl CoA 
in CML LSCs is thought to be derived from both fatty acid oxidation and shunting of 
pyruvate (an NAD+-dependent process) derived from glycolysis71 - the net effects of 
which are increased reliance on the TCA cycle and OXPHOS. Within the TCA cycle, 
the effects of wild type (WT) and mutant (MUT) IDH1 and IDH2 forms are well 
studied in AML153, 154, 244. In this and other respects, effects of altered levels of 
metabolites impact directly on the function of epigenetic regulators in CML and AML. 
These include SIRT1, which mediates NAD+-dependent histone and non-histone 
deacetylation; histone acetyltransferases (KAT3A and KAT3B), which utilise acetyl 
groups (Ac) from acetyl CoA to acetylate histone and non-histone targets; the 
inhibitory effects of 2-hydroxyglutarate (2-HG) on histone demethylation (KDM6A) 
and the hydroxylation (OH) of 5-methylcytosine (by TET1 and TET2) that leads to 
DNA demethylation; DNA and histone methyltransferases (DNMT3A, EZH2, DOT1L) 
which utilise methyl groups (Me) from S-adenosyl methionine produced via amino 
acid metabolism. DNA damage arising as a consequence of OXPHOS-driven ROS 
production by mitochondria is also shown. α-KG, alpha-ketoglutarate. 
Box 1. Selective cell surface markers in CML and AML LSCs.  
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For many years, normal HSCs and LSCs from CML or AML patient samples have 
been purified by fluorescence-activated cell sorting (FACS) using the same sets of 
cell surface markers - making them immunophenotypically indistinguishable. In 
recent years, several LSC-selective cell surface markers have been identified that 
may serve as biomarkers for LSC enrichment or for disease progression, or as drug 
targets. The potential utility of these cell surface markers as drug targets is 
exemplified by gemtuzumab ozogamicin (GO) - the first humanised anti-CD33 
monoclonal antibody conjugated to the toxic antibiotic calicheamicin (see the table). 
GO leads to improved outcomes in combination with conventional chemotherapy in 
favourable and intermediate risk AML patients219. Although pre-clinical evidence in 
acute promyelocytic leukemia would predict that GO is more effective on leukemias 
where the LSCs have emerged from more mature normal progenitor cells245, the 
situation is likely to be different in favourable risk AML patients. In these patients, the 
efficacy of GO could be explained if the CD33- pre-leukemic LSCs are non-
proliferative, and further mutations leading to leukemic transformation occur in a 
more mature immunophenotypic CD33+ LSC compartment246. In this scenario, the 
mature LSCs would be eradicated by GO, but the non-proliferative pre-LSCs would 
remain, resulting in relapse in the absence of additional consolidation therapy. 
Recent preclinical studies have also explored the possibility of using gene-edited 
stem cells to enable CD33-directed immunotherapies in AML247. Interestingly, 
preliminary preclinical studies of GO in CML LSCs showed efficacy248, and isolated 
case reports have demonstrated clinical responses249. 
 
MARKER ALIAS  DESCRIPTION INHIBITOR(S) LEUKEMIA 
TYPE 
REF. 
CD9 TSPAN29 
 
leukocyte 
antigen MIC3 
ALB6 (anti-CD9 
monoclonal Ab); 
CML, AML 250, 251 
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PAINS-13 (anti-
CD9 monoclonal 
Ab)  
CD25 
 
IL2RA  
 
-chain of the 
high-affinity IL-2 
receptor 
denileukin 
diftitox (IL-2 and 
diphtheria toxin 
fusion protein) 
CML, AML 252, 253 
CD26 
 
DPP4 
 
serine 
exopeptidase 
S9B family 
member. 
gliptins (e.g. 
sitagliptin) 
CML, AML 
(FLT3-ITD)  
254 
CD32 FCGR2A, 
FCGR2B, 
FCGR2C  
 
Fc-γ receptor II clone 2B6 (anti-
FCGR2B 
monoclonal Ab); 
MGD010 
(CD32B and 
CD79B DART 
bi-specific Ab-
based molecule) 
AML 253 
CD33  SIGLEC3  
 
myeloid cell 
surface antigen 
vadastuximab 
talirine (Ab-drug 
conjugate); 
gemtuzumab 
ozogamicin (Ab-
drug conjugate) 
AML, CML 250, 255 
CD47  MER6  
 
 
receptor for 
SIRPα  
 
Hu5F9-G4 (anti-
CD47 
monoclonal Ab); 
TTI-621 (SIRPα 
binding domain 
and IgG Fc 
fusion protein); 
INBRX-103 
(anti-CD47 
monoclonal Ab) 
BP-CML, AML 256, 257 
CD52  HE5  
 
Campath-1 
antigen 
alemtuzumab 
(anti-CD52 
monoclonal Ab) 
BP-CML, AML 258 
CD82 TSPAN27  
 
tetraspanin-27 none AML 259 
CD93 
 
MXRA4  
 
complement 
component 1 Q 
subcomponent 
receptor 1 
none CML, AML 260, 261 
CD96 TACTILE  
 
T-cell surface 
protein tactile 
none AML 262 
CD97 ADGRE5  
 
adhesion G 
protein-coupled 
receptor E5 
troglitazone; 
retinoic acid 
AML 259 
CD99 MIC2  
 
T-cell surface 
glycoprotein E2 
clofarabine; 
cladribine 
AML 263, 264 
CD103 ITGAE  
 
integrin subunit 
αE 
none AML 259 
CD123 IL3RA  
 
interleukin 3 
receptor subunit 
α 
SGN-123A (Ab-
drug conjugate); 
IMGN632 (Ab-
drug conjugate) 
 
AML, CML 250 
CD371 CLEC12A  C-type lectin MCLA-117 (bi- AML, CML 250, 265 
Vetrie et al. (2019)      NRC-17-023   
45 
 
 domain family 
12 member A 
specific 
CLEC12A and 
CD3 Ab) 
IL1RAP IL1R3  
 
interleukin 1 
receptor 
accessory 
protein 
IL1RAP 
monoclonal Ab 
CML, AML 266, 267 
TIM3 HAVCR2  
 
hepatitis A virus 
cellular receptor 
2 
 
TSR-022 (anti-
TIM3 
monoclonal Ab) 
AML 268 
  
  
Glossary  
Philadelphia chromosome: The chromosomal abnormality characteristic of CML 
cells that arises from a reciprocal translocation between chromosomes 9 and 22. 
relative survival rate: the percentage survival of individuals with leukemia after 
taking into account death rates of individuals without leukemia. 
immunophenotype: a population of cells characterized by markers expressed on 
the cell surface as determined by flow cytometry. 
chimerism: the relative proportions of human to mouse cells that result when human 
cells are engrafted into the bone marrow of immunocompromised mice.  
clonal hematopoeisis of indeterminant potential: a process that occurs in some 
older individuals whereby DNA mutations in HSCs result in the accumulation of 
clonally expanded populations of hematopoietic cells. 
hemangioblasts: multipotent precursor cells that can give rise to both HSCs and 
enthothelial cells. 
oxidative phosphorylation: the mitochondrial process in which electrons are 
transferred from NADH or FADH2 to oxygen (O2) through a series of carriers and 
protein complexes to produce ATP from ADP and phosphate. 
BH3-mimetic: one of a class of compounds that bind to a hydrophobic groove found 
in anti-apoptotic proteins and prevents them from binding to the BH3 domain of the 
BCL-2 family of proteins. 
 
